Version 2 2024-06-04, 15:29Version 2 2024-06-04, 15:29
Version 1 2018-07-09, 14:33Version 1 2018-07-09, 14:33
journal contribution
posted on 2024-06-04, 15:29authored byKenneth Aldape, Samirkumar B Amin, David M Ashley, Jill S Barnholtz-Sloan, Amanda J Bates, Rameen Beroukhim, Christoph Bock, Daniel J Brat, Elizabeth B Claus, Joseph F Costello, John F de Groot, Gaetano Finocchiaro, Pim J French, Hui K Gan, Brent Griffith, Christel C Herold-Mende, Craig Horbinski, Antonio Iavarone, Steven N Kalkanis, Konstantina Karabatsou, Mustafa Khasraw, Hoon Kim, Mathilde CM Kouwenhoven, Kerrie L McDonald, Hrvoje Miletic, Do-Hyun Nam, Ho Keung Ng, Simone P Niclou, Houtan Noushmehr, D Ryan Ormond, Laila M Poisson, Guido Reifenberger, Federico Roncaroli, Jason K Sa, Peter AE Sillevis Smitt, Marion Smits, Camila F Souza, Ghazaleh Tabatabai, Erwin G Van Meir, Roel GW Verhaak
Adult diffuse gliomas are a diverse group of brain neoplasms that inflict a high emotional toll on patients and their families. The Cancer Genome Atlas and similar projects have provided a comprehensive understanding of the somatic alterations and molecular subtypes of glioma at diagnosis. However, gliomas undergo significant cellular and molecular evolution during disease progression. We review the current knowledge on the genomic and epigenetic abnormalities in primary tumors and after disease recurrence, highlight the gaps in the literature, and elaborate on the need for a new multi-institutional effort to bridge these knowledge gaps and how the Glioma Longitudinal Analysis Consortium (GLASS) aims to systemically catalog the longitudinal changes in gliomas. The GLASS initiative will provide essential insights into the evolution of glioma toward a lethal phenotype, with the potential to reveal targetable vulnerabilities and, ultimately, improved outcomes for a patient population in need.